Publications

Detailed Information

Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease

DC Field Value Language
dc.contributor.authorLee, E. S.-
dc.contributor.authorKim, N.-
dc.contributor.authorLee, S. H.-
dc.contributor.authorPark, Y. S.-
dc.contributor.authorJeong, S. H.-
dc.contributor.authorJung, H. C.-
dc.contributor.authorSong, I. S.-
dc.contributor.authorLee, D. H.-
dc.contributor.authorKim, J. W.-
dc.date.accessioned2012-05-24T05:39:21Z-
dc.date.available2012-05-24T05:39:21Z-
dc.date.issued2009-07-15-
dc.identifier.citationALIMENTARY PHARMACOLOGY & THERAPEUTICS; Vol.30 2; 154-164ko_KR
dc.identifier.issn0269-2813-
dc.identifier.urihttps://hdl.handle.net/10371/76410-
dc.description.abstractP>Background There has been no report on the response to proton pump inhibitor (PPI) therapy and on-demand or the relapse rate of non-erosive reflux disease (NERD) and erosive oesophagitis in Korea. Aim To compare the risk factors, clinical symptoms and PPI responses between patients with erosive oesophagitis and NERD patients. Methods A survey was performed prospectively in the erosive oesophagitis (205 patients) and NERD group (200 patients). Clinical symptoms, risk factors and PPI responses were analysed. On-demand therapy and the relapse rate of GERD symptoms were investigated during a one-year follow-up. Results BMI >= 25 (OR 3.0, 95% CI 1.1-8.3), alcohol use (OR 2.9, 95% CI 1.0-8.3), hiatal hernia (OR 5.0, 95% CI 1.2-20) and triglyceride >= 150 mg/dL (OR 4.0, 95% CI 1.7-10) were more common in the erosive oesophagitis group than in the NERD group by multivariate analysis. The ratio of oesophageal to extra-oesophageal symptoms was higher in the erosive oesophagitis group compared with the NERD group (P < 0.001). The PPI response rates at 8 weeks were different (P = 0.02); refractory rates were higher in the NERD group (16.7%) compared with the erosive oesophagitis group (6.0%). However, there was no significant difference between the two groups in on-demand therapy or the relapse rate. Conclusion These results suggest that the underlying pathogenic mechanisms of erosive oesophagitis and NERD are distinct.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.titleComparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux diseaseko_KR
dc.typeArticleko_KR
dc.identifier.doi10.1111/j.1365-2036.2009.04021.x-
dc.citation.journaltitleALIMENTARY PHARMACOLOGY & THERAPEUTICS-
dc.description.citedreferenceChung SJ, 2008, GUT, V57, P1360, DOI 10.1136/gut.2007.147090-
dc.description.citedreferenceKim N, 2008, ALIMENT PHARM THERAP, V27, P173, DOI 10.1111/j.1365-2036.2007.03561.x-
dc.description.citedreferencePace F, 2007, ALIMENT PHARM THERAP, V26, P195, DOI 10.1111/j.1365-2036.2007.03381.x-
dc.description.citedreferenceFass R, 2007, J CLIN GASTROENTEROL, V41, P131-
dc.description.citedreferenceGlatzel D, 2007, DIGESTION, V75, P69, DOI 10.1159/000101085-
dc.description.citedreferenceVakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x-
dc.description.citedreferenceMoayyedi P, 2006, LANCET, V367, P2086-
dc.description.citedreferenceDeVault KR, 2006, ALIMENT PHARM THERAP, V23, P33-
dc.description.citedreferenceFass R, 2006, CLIN GASTROENTEROL H, V4, P50, DOI 10.1053/S1542-3565(05)00860-8-
dc.description.citedreferenceAro P, 2005, GUT, V54, P1377, DOI 10.1136/gut.2004.057497-
dc.description.citedreferenceHampel H, 2005, ANN INTERN MED, V143, P199-
dc.description.citedreferenceSjostedt S, 2005, ALIMENT PHARM THERAP, V22, P183, DOI 10.1111/j.1365-2036.2005.02553.x-
dc.description.citedreferenceChen MH, 2005, SCAND J GASTROENTERO, V40, P759, DOI 10.1080/00365520510015610-
dc.description.citedreferenceFock KM, 2005, WORLD J GASTROENTERO, V11, P3091-
dc.description.citedreferenceDent J, 2005, GUT, V54, P710, DOI 10.1136/gut.2004.051821-
dc.description.citedreferenceFujiwara Y, 2005, AM J GASTROENTEROL, V100, P754, DOI 10.1111/j.1572-0241.2005.40966.x-
dc.description.citedreferenceCho YS, 2005, AM J GASTROENTEROL, V100, P747, DOI 10.1111/j.1572-0241.2005.41245.x-
dc.description.citedreferenceBarlow WJ, 2005, GASTROENTEROLOGY, V128, P771, DOI 10.1053/j.gastro.2004.08.014-
dc.description.citedreferenceFujiwara Y, 2005, J GASTROEN HEPATOL, V20, P26, DOI 10.1111/j.1400-1746.2004.03521.x-
dc.description.citedreferenceDonnellan C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003245.pub2-
dc.description.citedreferenceNilsson M, 2004, SCAND J GASTROENTERO, V39, P1040, DOI 10.1080/00365520410003498-
dc.description.citedreferenceWong WM, 2004, ALIMENT PHARM THERAP, V20, P803, DOI 10.1111/j.1365-2036.2004.02198.x-
dc.description.citedreferenceDean BB, 2004, CLIN GASTROENTEROL H, V2, P656, DOI 10.1053/S1542-3565(04)00288-5-
dc.description.citedreferenceWang JH, 2004, WORLD J GASTROENTERO, V10, P1647-
dc.description.citedreferenceRosaida MS, 2004, EUR J GASTROEN HEPAT, V16, P495, DOI 10.1097/01.meg.0000108291.74393.2c-
dc.description.citedreferenceFock KM, 2004, J GASTROEN HEPATOL, V19, P357-
dc.description.citedreferenceSHIWAKU K, 2004, LANCET, V363, P157-
dc.description.citedreferenceOkamoto K, 2003, DIGEST DIS SCI, V48, P2237-
dc.description.citedreferenceWong WM, 2003, ALIMENT PHARM THERAP, V18, P595, DOI 10.1046/j.1365-2036.2003.01737.x-
dc.description.citedreferenceInadomi JM, 2003, AM J GASTROENTEROL, V98, P1940, DOI 10.1016/S0002-9270(03)00628-2-
dc.description.citedreferenceWatanabe Y, 2003, SCAND J GASTROENTERO, V38, P807, DOI 10.1080/00365520310004506-
dc.description.citedreferenceInamori M, 2003, J GASTROEN HEPATOL, V18, P172-
dc.description.citedreferenceHu WHC, 2002, ALIMENT PHARM THERAP, V16, P2081, DOI 10.1046/j.0269-2813.2002.01377.x-
dc.description.citedreferenceWong WM, 2002, ALIMENT PHARM THERAP, V16, P2037, DOI 10.1046/j.0269-2813.2002.01373x-
dc.description.citedreferenceJohnsson F, 2002, SCAND J GASTROENTERO, V37, P642-
dc.description.citedreferenceLee SJ, 2001, J GASTROEN HEPATOL, V16, P373-
dc.description.citedreferenceRichter JE, 2001, AM J GASTROENTEROL, V96, P656-
dc.description.citedreferenceSharma VK, 2001, ALIMENT PHARM THERAP, V15, P227-
dc.description.citedreferenceFass R, 2000, ALIMENT PHARM THERAP, V14, P1595-
dc.description.citedreferenceRichter JE, 2000, AM J GASTROENTEROL, V95, P3071-
dc.description.citedreferenceRichter JE, 2000, ARCH INTERN MED, V160, P1803-
dc.description.citedreferenceRichter JE, 2000, ARCH INTERN MED, V160, P1810-
dc.description.citedreferenceGoh KL, 2000, J GASTROEN HEPATOL, V15, P230-
dc.description.citedreferenceLEE S, 2000, KOREAN J NEUROGASTRO, V6, P1-
dc.description.citedreferenceLundell LR, 1999, GUT, V45, P172-
dc.description.citedreferenceFurukawa N, 1999, J GASTROENTEROL, V34, P441-
dc.description.citedreferenceLind T, 1999, ALIMENT PHARM THERAP, V13, P907-
dc.description.citedreferenceDent J, 1998, DIGESTION, V59, P433-
dc.description.citedreferenceCarlsson R, 1998, EUR J GASTROEN HEPAT, V10, P119-
dc.description.citedreferenceVenables TL, 1997, SCAND J GASTROENTERO, V32, P965-
dc.description.citedreferenceGalmiche JP, 1997, ALIMENT PHARM THERAP, V11, P765-
dc.description.citedreferenceYeh C, 1997, DIGEST DIS SCI, V42, P702-
dc.description.citedreferenceIsolauri J, 1997, AM J GASTROENTEROL, V92, P37-
dc.description.citedreferenceCastell DO, 1996, AM J GASTROENTEROL, V91, P1749-
dc.description.citedreferenceBate CM, 1996, ALIMENT PHARM THERAP, V10, P547-
dc.description.citedreferenceCOLLEN MJ, 1995, AM J GASTROENTEROL, V90, P1053-
dc.description.citedreferenceBARDHAN KD, 1995, ALIMENT PHARM THERAP, V9, P145-
dc.description.citedreferenceKLAUSER AG, 1990, LANCET, V335, P205-
dc.description.tc7-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share